9月12日，博腾股份盘中下跌2.03%，截至10:02，报25.06元/股，成交1.89亿元，换手率1.48%，总市值 136.69亿元。 资金流向方面，主力资金净流出1596.03万元，特大单买入334.17万元，占比1.76%，卖出814.07万元， 占比4.30%；大单买入2986.50万元，占比15.77%，卖出4102.63万元，占比21.67%。 博腾股份今年以来股价涨58.91%，近5个交易日跌3.24%，近20日涨5.21%，近60日涨62.10%。 博腾股份所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：CRO概念、抗癌治 癌、抗癌药物、创新药、生物医药等。 截至8月29日，博腾股份股东户数5.27万，较上期减少0.75%；人均流通股9502股，较上期增加0.75%。 2025年1月-6月，博腾股份实现营业收入16.21亿元，同比增长19.88%；归母净利润2705.95万元，同比增 长115.91%。 分红方面，博腾股份A股上市后累计派现11.93亿元。近三年，累计派现8.66亿元。 机构持仓方面，截止2025年6月30日，博腾股份十大流通股东中，香港中央结算有限公司位 ...

截至8月29日，博腾股份股东户数5.27万，较上期减少0.75%；人均流通股9502股，较上期增加0.75%。 2025年1月-6月，博腾股份实现营业收入16.21亿元，同比增长19.88%；归母净利润2705.95万元，同比增 长115.91%。 分红方面，博腾股份A股上市后累计派现11.93亿元。近三年，累计派现8.66亿元。 机构持仓方面，截止2025年6月30日，博腾股份十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股1075.89万股，相比上期增加238.86万股。天弘医药创新A（010654）位居第六大流通股 东，持股639.80万股，相比上期减少51.39万股。南方中证1000ETF（512100）位居第九大流通股东，持 股302.18万股，为新进股东。华宝中证医疗ETF（512170）、中欧医疗健康混合A（003095）、中信建 投医改A（002408）退出十大流通股东之列。 9月9日，博腾股份盘中上涨2.02%，截至09:58，报26.22元/股，成交2.03亿元，换手率1.58%，总市值 143.02亿元。 资金流向方面，主力资金净流出52.23万元，特大单买入975.58万 ...

Core Points - The company announced a change in the purpose of its share repurchase program, shifting from "for implementing equity incentives or employee stock ownership plans" to "for cancellation and reduction of registered capital" [2] - A total of 2,022,344 shares from the 2022 repurchase will be canceled, reducing the total share capital from 545,464,520 shares to 543,442,176 shares [2] - The registered capital will decrease from RMB 545,464,520 to RMB 543,442,176 following the cancellation of shares [2] - The company has notified creditors of their rights to request debt repayment or guarantees within 45 days from the announcement date [2] - If creditors do not exercise their rights within the specified period, the share cancellation will proceed according to legal procedures [2]

Group 1 - The company announced that its first extraordinary general meeting of shareholders for 2025 will be held on September 8, 2025 [2] - The meeting will review and approve several proposals, including the proposal to change the purpose of part of the repurchased shares and to cancel them [2]

Group 1 - The company announced the cancellation of part of the repurchased shares and a capital reduction on September 8, 2025 [1] - The board meetings held on August 21, 2025, and the extraordinary shareholders' meeting on September 8, 2025, approved the change in the purpose of the repurchased shares [1] - The repurchased shares, originally intended for employee stock incentive plans, will now be used for cancellation and reduction of registered capital [1] Group 2 - A total of 2,022,344 shares will be canceled, reducing the total share capital from 545,464,520 shares to 543,442,176 shares [1] - The registered capital will decrease from RMB 545,464,520 to RMB 543,442,176 following the cancellation [1] - Creditors have 45 days from the announcement date to claim debts or request guarantees due to the capital reduction [1]

1、本次股东会召开期间没有增加、否决或变更议案情况发生； 2、本次股东会不涉及变更前次股东会决议； 股票代码：300363 股票简称：博腾股份 公告编号：2025-048 号 重庆博腾制药科技股份有限公司 2025 年第一次临时股东会决议公告 公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 同意 240,358,789 股，占参加本次股东会的股东所持有表决权股份总数 99.9297%；反对 127,300 股，占参加本次股东会的股东所持有表决权股份总数 0.0529%；弃权 41,910 股，占参加本次股东会的股东所持有表决权股份总数 0.0174%。 3、本次股东会采取现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 重庆博腾制药科技股份有限公司（以下简称"公司"）2025 年第一次临时 股东会于 2025 年 9 月 8 日（星期一）14:30 在重庆市北碚区云图路 7 号公司研发 大楼 2-2 会议室以现场投票与网络投票相结合的方式召开。本次股东会由公司董 事会召集，董事长居年丰因其他公务安排无法履行本次股东会主持人职务，经公 司半 ...

北京市万商天勤律师事务所 关于重庆博腾制药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 1 北京市万商天勤律师事务所关于 重庆博腾制药科技股份有限公司 2025 年第一次临时股东会的 法律意见书 致：重庆博腾制药科技股份有限公司 北京市万商天勤律师事务所（以下简称"本所"）接受重庆博腾制药科技股 份有限公司（以下简称"公司"）的委托，指派律师出席了公司召开的 2025 年 第一次临时股东会。根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、法规和规范性 文件以及《重庆博腾制药科技股份有限公司章程》（以下简称"《公司章程》"） 的要求，就公司 2025 年第一次临时股东会（以下简称"本次临时股东会"）的 相关事宜出具本法律意见书。 公司已向本所律师提供了本所律师认为出具本法律意见书必要的文件资料， 本所律师对该等文件和资料进行了核查、验证，并据此出具法律意见。 本所律师仅就本次临时股东会的召集、召开程序、出席会议人员资格、召 集人资格及会议表决程序、表决结果是否符合《公司法》、《股东会规则》以及 《公司章程》发表意见。 本所律师同意 ...

重庆博腾制药科技股份有限公司（以下简称"公司"）分别于 2025 年 8 月 21 日召开第六届董事会第三次会议和第六届监事会第二次会议、于 2025 年 9 月 8 日召开 2025 年第一次临时股东会，审议通过《关于变更部分回购股份用途并 注销的议案》，同意对公司于 2022 年 8 月 4 日召开的第五届董事会第六次临时 会议审议通过的《关于以集中竞价交易方式回购股份的议案》的回购股份（以下 简称"2022 年回购"）用途进行变更，由"用于实施股权激励或员工持股计划" 变更为"用于注销并减少公司注册资本"，并对 2022 年回购的全部股份，共计 2,022,344 股，予以注销。具体情况详见公司分别于 2025 年 8 月 23 日在巨潮资 讯网（www.cninfo.com.cn）披露的《关于变更部分回购股份用途并注销的公告》 （公告编号：2025-045号）、于2025 年9 月8日在巨潮资讯网（www.cninfo.com.cn） 披露的《2025 年第一次临时股东会决议公告》（公告编号：2025-048 号）。 上述注销实施完毕后，公司总股本将由 545,464,520 股变更为 543,442 ...

Core Viewpoint - The medical services sector experienced a significant increase of 3.79% on September 5, with Zhaoyan New Drug leading the gains [1] Market Performance - The Shanghai Composite Index closed at 3812.51, up 1.24% - The Shenzhen Component Index closed at 12590.56, up 3.89% [1] Individual Stock Performance - Zhaoyan New Drug (603127) closed at 34.01, up 9.99% with a trading volume of 578,000 shares and a transaction value of 1.905 billion yuan - Tiger Medical (300347) closed at 66.58, up 6.66% with a trading volume of 146,300 shares and a transaction value of 950 million yuan - Kailaiying (002821) closed at 108.27, up 6.44% with a trading volume of 114,500 shares and a transaction value of 1.213 billion yuan - Posens (301257) closed at 49.20, up 5.81% with a trading volume of 84,700 shares and a transaction value of 407 million yuan - Kanglong Chemical (300759) closed at 31.30, up 5.56% with a trading volume of 615,400 shares and a transaction value of 1.887 billion yuan - WuXi AppTec (603259) closed at 107.40, up 5.36% with a trading volume of 802,300 shares and a transaction value of 8.39 billion yuan - Jiuzhou Pharmaceutical (603456) closed at 19.15, up 5.22% with a trading volume of 441,000 shares and a transaction value of 827 million yuan - ST Biological (000504) closed at 9.68, up 4.99% with a trading volume of 49,800 shares and a transaction value of 4.749 million yuan - Nossger (301333) closed at 58.02, up 4.94% with a trading volume of 56,100 shares and a transaction value of 32.2 million yuan - Boteng Co., Ltd. (300363) closed at 25.90, up 4.73% with a trading volume of 396,800 shares and a transaction value of 1.011 billion yuan [1] Capital Flow - The medical services sector saw a net inflow of 423 million yuan from institutional investors, while retail investors experienced a net outflow of 58.5864 million yuan [1]

Group 1 - The CRO (Contract Research Organization) concept stocks in the A-share market have shown strong performance, with notable gains in several companies [1] - Zhaoyan New Drug approached the daily limit increase with a rise of 9.12%, while other companies like Kailaiying, Nossger, and Kanglong Chemical also saw increases exceeding 5% [1][2] - The total market capitalization of Zhaoyan New Drug is 25.3 billion, and it has achieved a year-to-date increase of 103.06% [2] Group 2 - Kailaiying's stock rose by 5.48%, with a total market capitalization of 38.7 billion and a year-to-date increase of 42.84% [2] - Nossger and Kanglong Chemical experienced increases of 5.44% and 5.19%, respectively, with market capitalizations of 5.631 billion and 55.5 billion [2] - Other companies such as Sunshine Nuohuo and Boteng also reported gains of over 5%, with year-to-date increases of 109.05% and 64.55% respectively [2]